

ISSN: 2008-3289  
eISSN: 2008-4447



# IJM Iranian Journal of *Microbiology*

Bimonthly



Tehran University  
of Medical Sciences

pISSN: 2008-3289

eISSN: 2008-4447

CHAIRMAN AND EDITOR:

**Mohammad Mehdi Feizabadi**

MAKE A SUBMISSION

## INFORMATION

Publication Fee

For Readers

For Authors

For Librarians



[HOME](#) [ABOUT](#) [CURRENT](#) [ARCHIVES](#) [INDEXING & ABSTRACTING](#) [FOR AUTHORS](#)

Search

## Editorial Board

### Chairman & Editor:

[Mohammad Mehdi Feizabadi](#), Ph.D.

Professor, Department of Microbiology, [Tehran University of Medical Sciences](#), Tehran, Iran.

### Editorial Board:

[Deanna Gibson](#), Ph.D.

Associate Professor, Department of Biology, University of British Columbia, Okanagan Campus, Kelowna, British Columbia, Canada.

[Gholamreza Salehi Jouzani](#) Ph.D.

Professor, Microbial Biotechnology and Biosafety Department, Agricultural Biotechnology Research Institute, Karaj, Iran.

[Gilla Yavarian](#) Ph.D.

Associate Professor, Department of Virology, [Tehran University of Medical Sciences](#), Tehran, Iran.

[Ingrid S Surono](#), MSc, Ph.D.

Associate Professor, Department of Food Technology, Bina Nusantara University, Jakarta, Indonesia.

[İpek Kurtböke](#), Ph.D.

Associate Professor, School of Science and Education, Faculty of Science, Health and Education, University of the Sunshine Coast Maroochydore DC, Australia.

[Leonid Titov](#), M.D., Ph.D.

Professor, Belarusian Research Institute for Epidemiology and Microbiology, Minsk, Belarus.

[Mahshid Nasehi](#), M.D.

Associate Professor, Department of Epidemiology, Iran University of Medical Sciences, Tehran, Iran.

[Manuchehr Makvandi](#) Ph.D.

Professor, Department of Virology, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

[Masoud Hajizadeh Manjili](#), Ph.D.

Professor, Department of Microbiology & Immunology, Virginia Commonwealth University, USA.

[Mehrnaz Rasoolinejad](#), M.D.

Professor, Department of Infectious Diseases, [Tehran University of Medical Sciences](#), Tehran, Iran.

Mina Tabrizi, M.D., Ph.D. 


Associate professor, Department of Genetics, [Tehran University of Medical Sciences](http://www.tums.ac.ir), Tehran, Iran.

Mohammad Katouli, Ph.D. 

Professor, School of Health and Sport Science, Faculty of Science, Health and Education, University of the Sunshine Coast  
Maroochydore DC, Australia.

Mohammad Mehdi Aslani, Ph.D. 


Professor, Department of Bacteriology, Pasteur Institute of Iran, Tehran, Iran.

Mostafa Rezaeian, Ph.D. 

Professor, Department of Medical Parasitology and Mycology, [Tehran University of Medical Sciences](http://www.tums.ac.ir), Tehran, Iran.

Rouha Kasra Kermanshahi, Ph.D. 

Professor, Department of Biological Science, Alzahra University, Vanak, Tehran, Iran.

Saeid Bouzari, Ph.D. 

Professor, Department of Molecular Biology, Pasteur Institute of Iran, Tehran, Iran

Saeid Bokaei, D.V.M., Ph.D. 

Professor, Department of Epidemiology, University of Tehran, Tehran, Iran.

Sedigheh Zakeri, Ph.D. 

Professor, Malaria and Vector Research Group, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran.

Sirus Jafari, M.D. 

Associate Professor, Department of Infectious Diseases, [Tehran University of Medical Sciences](http://www.tums.ac.ir), Tehran, Iran.

Taghi Zahraei Salehi, D.V.M., Ph.D. 

Professor, Department of Veterinary Microbiology, University of Tehran, Tehran, Iran.

Willem B. van Leeuwen, Ph.D. 

Professor, Leiden Centre for Applied Bioscience, University of Leiden, The Netherlands.



[HOME](#) [ABOUT](#) [CURRENT](#) [ARCHIVES](#) [INDEXING & ABSTRACTING](#) [FOR AUTHORS](#)

Search

[HOME](#) [ARCHIVES](#) Vol 11 No 2 (2019)

PUBLISHED: 2019-06-01

## REVIEW ARTICLE(S)

### Priorities in prevention and control of flood hazards in Iran 2019 massive flood

Laleh Sharifi, Saied Bokaie

80-84

[XML](#)

[PDF \(236KB\)](#)

[Downloads : 35](#) | [Views : 181](#)

## MINI REVIEW

### Possible viral infections in flood disasters: a review considering 2019 spring floods in Iran

Jila Yavarian, Nazanin Zahra Shafiei-Jandaghi, Talat Mokhtari-Azad

85-89

[XML](#)

[PDF \(236KB\)](#)

[Downloads : 30](#) | [Views : 222](#)

## ORIGINAL ARTICLE(S)

### Blood culture and antimicrobial susceptibility pattern of bacteria and fungi isolated from febrile neutropenic patients treated with chemotherapy at Taleghani hospital, Tehran

Rozita Khodashahi, Mojdeh Hakemi-Vala, Masoud Mardani, Sara Abolghasemi, Ensieh Lotfali, Zahra Arab-Mazar, Naser Omid, Sepideh Ghasemshahi

90-97

[XML](#)

[PDF \(502KB\)](#)

[Downloads : 49](#) | [Views : 126](#)

### Molecular analysis and antimicrobial resistance pattern of distinct strains of *Pseudomonas aeruginosa* isolated from cystic fibrosis patients in Iran

Mohammad Emameini, Davood Kalantar-Neyestanaki, Leila Jabalameli, Mojtaba Hashemi, Reza Beigverdi, Fereshteh Jabalameli  
98-107

 XML  PDF (628KB)  Downloads : 55 |  Views : 125

### Prevalence of *Candida* bloodstream isolates from patients in two hospitals in Vietnam

Nguyen Duy Bac, Le Tran Anh, Le Bach Quang, Nguyen Khac Luc, Tran Thi Thanh Nga, Minoru Nagi, Miyazaki Yoshitsugu, Hoang Thi Thu Ha, Dang Duc Anh, Do Quyet, Do Ngoc Anh  
108-113

 XML  PDF (276KB)  Downloads : 21 |  Views : 111

### Identification of *Candida* spp. isolated from oral mucosa in patients with leukemias and lymphomas in Iran

Sara Sara Hamzehee, Davood Kalantar-Neyestanaki, Mohammad Ali Mohammadi, Saeed Nasibi, Seyed Amin Ayatollahi Mousavi  
114-119

 XML  PDF (300KB)  Downloads : 47 |  Views : 258

### Identification of microorganisms in persistent/secondary endodontic infections with respect to clinical and radiographic findings: bacterial culture and molecular detection

Nazanin Zargar, Mahmoud Amin Marashi, Hengameh Ashraf, Rene Hakopian, Peyman Beigi  
120-128

 XML  PDF (376KB)  Downloads : 40 |  Views : 197

### Frequency of adenovirus serotype 8 in patients with Keratoconjunctivitis, in Ahvaz, Iran

Kolsoom Shafiei, Manoochehr Makvandi, Ali Teimoori, Alireza Samarbarfzadeh, Gholamreza Khataminia, Shahram Jalilian, Niloofar Neisi, Kimia Makvandi, Mehrdad Sadeghi Haj  
129-136

 XML  PDF (338KB)  Downloads : 28 |  Views : 227

### Effect of *Lactobacillus plantarum* IS-10506 on blood lipopolysaccharide level and immune response in HIV-infected children

Alpha Fardah Athiyyah, Herwina Brahmantya, Stephani Dwiastuti, Andy Darma, Dwiyanti Puspitasari, Dominicus Husada, Reza Ranuh, Anang Endaryanto, Ingrid Surono, Subijanto Marto Sudarmo  
137-144

 XML  PDF (347KB)  Downloads : 36 |  Views : 101

### Effect of the probiotic *Lactobacillus plantarum* IS-10506 on BDNF and 5HT stimulation: role of intestinal microbiota on the gut-brain axis

Reza Ranuh, Alpha Fardah Athiyyah, Andy Darma, Vitria Prasetyo Risky, Wibi Riawan, Ingrid S. Surono, Subijanto Marto Sudarmo  
145-150

 XML  PDF (678KB)  Downloads : 53 |  Views : 217

### Fecal human $\beta$ -defensin-2 (hBD-2) levels and gut microbiota patterns in preterm neonates with different feeding patterns

Brigitta I.R.V. Corebima, Rinawati Rohsiswatmo, Pramita Gayatri, Sanjay Patole  
151-159

[XML](#)[PDF \(350KB\)](#)[Downloads : 24](#) | [Views : 79](#)

### Effect of microencapsulation on *Saccharomyces cerevisiae* var. *boulardii* viability in the gastrointestinal tract and level of some blood biochemical factors in wistar rats

Hassan Ghorbani-Choboghlo, Donya Nikaein, Ali-Reza Khosravi, Reza Rahmani, Zohreh Farahnejad  
160-165

[XML](#)[PDF \(331KB\)](#)[Downloads : 42](#) | [Views : 86](#)

### Analysis of antibacterial and antibiofilm activity of purified recombinant Azurin from *Pseudomonas aeruginosa*

Hajar Mohammadi-Barzelighi, Bahram Nasr-Esfahani, Bita Bakhshi, Bahram Daraei, Sharareh Moghim, Hossein Fazeli  
166-176

[XML](#)[PDF \(602KB\)](#)[Downloads : 16](#) | [Views : 74](#)

### Antibacterial effect of chitosan from squid pens against *Porphyromonas gingivalis* bacteria

Latief Mooduto, Dian Agustin Wahjuningrum, Agatha Prita A, Cecilia G. J. Lunardhi  
177-180

[XML](#)[PDF \(260KB\)](#)[Downloads : 40](#) | [Views : 74](#)

### A simple method for in-house Pfu DNA polymerase purification for high-fidelity PCR amplification

Prabu Siva Sankar, Marimuthu Citartan, Aminah Ahmed Siti, Boris V. Skryabin, Timofey S. Rozhdestvensky, Goot Heah Khor, Thean Hock Tang  
181-186

[XML](#)[PDF \(419KB\)](#)[Downloads : 51](#) | [Views : 303](#)

## CASE REPORT(S)

### Bilateral septic arthritis of the knee caused by group B streptococci: a case report

Seyed Ali Dehghan Manshadi, Ramazanali Alizadeh, Mohammadreza Salehi, Arash Seifi, Mojgan Seifi  
187-190

[XML](#)[PDF \(182KB\)](#)[Downloads : 38](#) | [Views : 90](#)

## Effect of *Lactobacillus plantarum* IS-10506 on blood lipopolysaccharide level and immune response in HIV-infected children

Alpha Fardah Athiyyah<sup>1</sup>, Herwina Brahmantya<sup>1</sup>, Stephani Dwiastuti<sup>1</sup>, Andy Darma<sup>1</sup>, Dwiyanti Puspitasari<sup>1</sup>, Dominicus Husada<sup>1</sup>, **Reza Ranuh<sup>1</sup>**, Anang Endaryanto<sup>1</sup>, Ingrid Surono<sup>2</sup>, Subijanto Marto Sudarmo<sup>1</sup>

<sup>1</sup>Department of Child Health, Faculty of Medicine, Dr. Soetomo Hospital, Airlangga University, Surabaya, Indonesia

<sup>2</sup>Food Technology Department, Faculty of Engineering, Bina Nusantara University, Jakarta, Indonesia

Received: November 2018, Accepted: January 2019

### ABSTRACT

**Background and Objectives:** HIV enteropathy may cause disruption of the intestinal barrier, leading to a loss of CD4+ T cells, increased intestinal permeability, and microbial translocation. *Lactobacillus plantarum* IS-10506 has the ability to improve gut barrier function. This study investigated the effect of *L. plantarum* IS-10506 on a number of biomarkers of enteropathy-related damage in HIV-infected paediatric patients undergoing antiretroviral therapy (ARV).

**Materials and Methods:** A randomized, double-blind, placebo-controlled study was conducted on 2-18 year-old children, diagnosed as HIV infected according to the WHO 2007 criteria who had received ARV for  $\geq 6$  months. Subjects were excluded if ARV therapy was discontinued or the patients took probiotics  $\geq 2$  weeks prior to the study or during the study period. Subjects were randomized into a probiotic group and placebo group. The probiotic group received *L. plantarum* IS-10506  $2.86 \times 10^{10}$  cfu/day for 6 days. Blood lipopolysaccharide (LPS) level, serum CD4+ T cell count, serum CD8+ T cell count, CD4+/CD8+ T cell ratio, and faecal sIgA level were assessed as biomarkers.

**Results:** Twenty-one subjects completed this study. The blood LPS level decreased significantly in the probiotic group ( $p = 0.001$ ). There was no significant difference in absolute CD4+ T cell count, percent CD4+ cells, absolute CD8+ T cell count, CD4+/CD8+ T cell ratio, or faecal sIgA. No serious adverse events were reported.

**Conclusion:** The probiotic *L. plantarum* IS-10506 reduced the blood LPS level but showed no effect on the humoral mucosa and systemic immune response in HIV-infected children undergoing ARV therapy.

**Keywords:** Probiotics; *Lactobacillus plantarum* IS-10506; HIV infected children; Blood lipopolysaccharide; Immune responses

### INTRODUCTION

Human immunodeficiency virus (HIV) is a virus that infects and kills CD4+ T cells and plays an important role in the immune response to the invasion of pathogenic microorganisms (1). In 2016, there

\*Corresponding author: Alpha Fardah Athiyyah, MD, Department of Child Health, Faculty of Medicine, Dr. Soetomo Hospital, Airlangga University, Surabaya, Indonesia.  
Tel: +628123585507  
Email: alpha-f-a@fk.unair.ac.id

were up to 1.8 million newly infected patients, consisting of 1.7 million adults and 160 thousand children under 15 years of age (2).

Enteropathy commonly occurs following HIV infection (3). Enteropathy can cause microbial translocation from the intestinal lumen to the systemic blood circulation, thus stimulating chronic immune activation (4). The degree of this bacterial translocation can be reflected by the blood lipopolysaccharide (LPS) level, as LPS is the main component of the cell wall of Gram-negative bacteria, the predominant bacteria in the gastrointestinal tract (5, 6). A previous study showed that there is a significant increase in the plasma LPS level in patients with chronic HIV infection, compared with those without HIV (3). Although antiretroviral (ARV) therapy can suppress viral replication in HIV patients, it does not facilitate complete improvement and is unable to repair intestinal barrier injury, which causes microbial translocation and eventually stimulates chronic immune activation (7-9).

Probiotics are microorganisms that, in optimal amounts, can provide health benefits to their host (10) mainly because of their ability to enhance the mucosal immune response, repair intestinal barrier tight junctions, and help reduce the colonization and translocation of pathogenic microbes (11). Prior research has found that supplementation of probiotics in HIV-infected patients treated with ARV improved the health of the digestive system and patients' long-term prognosis (8).

*Lactobacillus plantarum* IS-10506 is a probiotic strain isolated from Indonesian fermented water buffalo milk known as "dadih" (12). Probiotic supplementation of *L. plantarum* IS-10506 and IS-20506 has been shown to inhibit apoptosis and intestinal brush border epithelial cell damage by inhibiting nuclear factor kappa B (NF- $\kappa$ B) and downregulating TNF- $\alpha$  receptor 1 (TNFR1) (13). The supplementation contributed to the repair of intestinal brush border epithelial damage after *E. coli* LPS exposure (13). We therefore investigated the effect of oral supplementation of *L. plantarum* IS-1050 on the amount of microbial translocation (as shown by the blood LPS level), serum CD4+ T cell counts, CD8+ T cell counts, CD4+/CD8+ T cell ratio (which reflects HIV infection progression), and faecal secretory IgA (a humoral immune parameter) in HIV-infected children receiving ARV therapy.

## MATERIALS AND METHODS

**Study design.** We designed a randomized double-blind placebo-controlled study (clinical trial number TCTR20180525003 from Thai Clinical Trial Registry), which was conducted from December 2012 to March 2013. An ethical clearance certificate was issued by the Dr. Soetomo Hospital Research Ethical Committee, with certificate number 217/Panke KKE/IX/2012. Subjects were recruited from the Intermediate Care of Infectious Disease Unit (ICIDU) outpatient clinic in Dr. Soetomo General Hospital, Surabaya, Indonesia.

Randomization was done independently by the pharmacist using simple random sampling. Subjects were allocated to two groups: a probiotic group and a placebo group. Those in the probiotic group received 700 mg of microencapsulated probiotic with a dose of  $2.86 \times 10^{10}$  cfu/day, given orally once daily for 6 weeks. The placebo group received 700 mg powdered maltodextrin, packaged and flavoured in the same manner as the probiotic, given once a day for 6 weeks. Both groups continued the standard ARV therapy during the study. The blood LPS level, absolute CD4+ T cell count, percent CD4, absolute CD8+ T cell count, CD4+/CD8+ ratio, and faecal sIgA were measured before and after treatment.

**Subjects.** Inclusion criteria were: (1) 2-18 years of age; (2) HIV infected, based on WHO 2007 immunological criteria for diagnosing HIV in children; (a) CD4 count less than 350 per mm<sup>3</sup> of blood in children 5 years or older, and/or (b) %CD4 < 30 among children younger than 12 months, %CD4 < 25 among children aged 12-35 months, %CD4 < 20 among children aged 36-59 months; (3) patients had received ARV therapy for a minimum of 6 months prior to the study; (4) parents or guardians agreed to participate and provided written informed consent. Exclusion criteria were: (1) HIV-infected patients who failed therapy (stopped ARV therapy) or (2) patients who took any probiotic 2 weeks before or during the study period.

**Probiotic.** The microencapsulated *L. plantarum* IS-10506 (GenBank accession number DQ860148) powder was given  $2.86 \times 10^{10}$  cfu/day for 6 days. The probiotic powder was prepared under aseptic conditions, and in every stage of production, viability and contamination were assessed using plate counts in



De Man, Rogosa and Sharpe (MRS) agar and Plate Count Agar (PCA), respectively.

**Blood lipopolysaccharide level.** The blood LPS level was measured pre- and post-treatment by ELISA using an Endotoxin Limulus Amoebocyte Lysate Assay (Thermo Scientific™ Pierce™ LAL Chromogenic Endotoxin Quantitation Kit, catalogue number 88282, Rockford, USA). For this procedure, the stock solution must be made using 1 mL of centrifuged blood serum. The blood LPS result was expressed in EU/mL. Finally, a conversion rate of 0.01 ng/mL of 0.1 EU/mL was used.

**Immunological analyses.** The absolute CD4+ T cell count, percent CD4, and absolute CD8+ T cell count were analysed by flow cytometry. Three millilitres of each blood samples with EDTA were analysed using flow cytometry (BD FACSCalibur, San Jose, USA) with BD Reagent (CD4 reagent catalogue No. 340383 and CD8 reagent catalogue No. 340344). Both the absolute count and percentage were obtained for the CD4+ and CD8+ T cell counts. The CD4+/CD8+ T cell ratio was obtained by calculation.

**Faecal secretory immunoglobulin A.** Stool samples were collected in a sterile stool container and immediately stored at -80°C. Faecal sIgA was determined using a solid phase direct ELISA sandwich method (Calbiotech, catalogue number SC221A, CA, USA). This method uses anti-human labelled horseradish peroxidase (HRP) as the secondary antibody and tetramethylbenzidine (TMB) as the calorimetric substrate (both from Sigma-Aldrich, St. Louis, MO, USA). Results are reported in mg/gram stool.

**Statistical analysis.** Descriptive analysis was followed by independent t test and Mann-Whitney U test to compare pre-treatment and post-treatment groups and determine the differences between placebo and probiotic groups. Data were analysed using a 95% level of confidence ( $\alpha = 0.05$ ). Statistical analyses were done using SPSS 15.0 for windows (IBM, New York, USA).

## RESULTS

Twenty-five subjects met the inclusion and exclusion criteria and were randomly classified into the

placebo group (n = 13) and probiotic group (n = 12). Four subjects, 2 subjects from the placebo group and 2 subjects from the probiotic group, discontinued participation owing to social reasons, such as distance of place of residence from Surabaya or inability to come for a required follow-up visit in 6 weeks. Therefore, a total of 21 subjects completed the study. Among these 21 subjects, 3 subjects were less than 5 years of age and 18 subjects were 5 years of age or older. Thus, based on WHO criteria, the percent CD4 criterion was applied to the 3 subjects aged < 5 years, while the absolute CD4+ T cell count criterion was applied to the 18 subjects aged  $\geq 5$  years.

There was no significant difference ( $p > 0.05$ ) in baseline characteristics, including the pre-treatment absolute CD4+ T cell counts, percent CD4, absolute CD8+ T cell counts, CD4+/CD8+ T cell ratio, and faecal sIgA level (Table 1); however, there was a significant difference ( $p = 0.01$ ) in the pre-treatment LPS level, which was higher in the probiotic group than in the placebo group. No serious side effects or other health issues, such as opportunistic infection, diarrhoea, or vomiting, were reported.

We conducted statistical analysis based on the difference in the pre- and post-treatment LPS level ( $\Delta$ LPS), absolute CD4+ T cell count ( $\Delta$ CD4+), percent CD4 ( $\Delta\%$ CD4), absolute CD8+ T cell count ( $\Delta$ CD8+), CD4+/CD8+ T cell ratio ( $\Delta$ CD4+/CD8+), and faecal sIgA level ( $\Delta$ sIgA). We found a significant reduction in the LPS level ( $p = 0.011$ ) in the probiotic group, whilst there was no significant difference in faecal sIgA, absolute CD4+ T cell count, percent CD4, absolute CD8+ T cell count, and CD4+/CD8+ T cell ratio between the probiotic and placebo group (Table 2). Interestingly, 6 weeks after intervention, the faecal sIgA level of probiotic group was significantly higher in the placebo group (Fig. 1). The post-treatment LPS level was lower than the pre-treatment faecal sIgA level in the probiotic group. However, there was a lower LPS level in the post treatment placebo group (Fig. 2).

## DISCUSSION

The development of highly active antiretroviral therapy (HAART) has turned HIV infection into a chronic disease. Virological suppression and CD4+ T cell counts increment effect can be obtained for 12 months following therapy. One of the target organs

**Table 1.** Baseline characteristics

Characteristic	Probiotic Group (n=10)	Placebo Group (n=11)	<i>p</i>
<b>Age</b>			
< 5 years old	2	1	0.586 <sup>a</sup>
≥ 5 years old	8	10	
<b>Sex</b>			
Male	4	7	0.395 <sup>a</sup>
Female	6	4	
<b>Nutritional Status</b>			
Normal	9	11	0.476 <sup>a</sup>
Poor	1	0	
<b>Place of Residence</b>			
Surabaya	6	6	1.000 <sup>a</sup>
Outside Surabaya	4	5	
<b>Length of ARV therapy</b>			
≤ 1 year	0	0	N/A
> 1 year	9	11	
<b>LPS level pre-treatment, mean (SD) pg/mL</b>	130.00 (32.66)	95.45 (22.96)	0.011 <sup>*c</sup>
<b>CD4+ T cell absolute count pre-treatment, mean (SD) cells/mm<sup>3</sup></b>	1023.50 (571.10)	995.50 (382.40)	0.903 <sup>c</sup>
<b>%CD4+ T cell pre-treatment, mean (SD)</b>	34.06 (17.74)	23.97 (N/A)	0.723 <sup>c</sup>
<b>CD8+ T cell absolute count pre-treatment, mean (SD) cells/mm<sup>3</sup></b>	1594.70 (554.46)	1821.73 (601.45)	0.381 <sup>c</sup>
<b>CD4+/CD8+ T cell ratio pre-treatment, mean (SD)</b>	0.77 (0.53)	0.61 (0.30)	0.622 <sup>b</sup>
<b>Faecal sIgA pre-treatment, mean (SD) mg/g stool</b>	259.71 (28.91)	302.53 (52.21)	0.032 <sup>*c</sup>

a tested using Fisher's exact test

b tested using Mann-Whitney U test

c tested using independent t-test

\* significant difference on ( $p < 0.05$ )

N/A: not analysed

**Table 2.** Pre- and post-treatment differences between the probiotic and placebo groups

	Probiotic Group		Placebo Group		<i>p</i>
	n	Mean (SD)	n	Mean (SD)	
ΔLPS level, pg/mL	10	-22.00 (24.86)	11	19.09 (23.00)	0.001 <sup>a,*</sup>
ΔCD4+ T cell absolute count, cells/mm <sup>3</sup>	8	4.50 (178.99)	10	12.50 (344.88)	0.953 <sup>a</sup>
Δ%CD4+ T cell	2	2.91 (5.18)	1	1.68 (N/A)	0.878 <sup>a</sup>
ΔCD8+ T cell absolute count, cells/mm <sup>3</sup>	10	-108.20 (346.63)	11	-7.36 (519.30)	0.611 <sup>a</sup>
ΔCD4+/CD8+ T cell ratio	10	0.0280 (0.1452)	11	0.0073 (0.0782)	0.684 <sup>a</sup>
ΔFaecal sIgA, mg/g stool	10	39.30 (28.10)	11	-7.04 (57.96)	0.057 <sup>b</sup>

a tested using independent t test

b tested using Mann-Whitney U test

\* significant difference on ( $p < 0.05$ )

NA: not analysed




Fig. 1. Comparison of faecal sIgA level (mg/g stool) between *L. plantarum* IS 10506- treated and placebo groups




Fig. 2. Comparison of blood LPS Level(EU/ml) between *L. plantarum* IS 10506- treated and placebo groups

of HIV infection is the gastrointestinal tract (14). In the immunopathogenesis of HIV, enteropathy often occurs in HIV-infected patients (15). Enteropathy can cause microbial translocation from the intestinal lumen to the systemic circulation (16). In normal conditions, microbes and their products in the gastrointestinal lumen will be phagocytosed in the lamina propria and mesenteric lymphatic circulation (6). However, in immunocompromised patients, this defence mechanism is dysfunctional.

Prior research has noted subtle decreases in IgA-producing plasma cells in the colon and duodenum of HIV-positive subjects relative to non-HIV subjects, which is thought to allow bacteria to translocate from the gut lumen into the systemic blood circulation (6). This translocation activates chronic systemic immune activation and persistent inflammation (17). In this study, we examined the blood LPS level to measure bacterial translocation (6), the faecal sIgA level to indicate the humoral mucosal immune response, and the absolute CD4+ T cell count, percent CD4, absolute CD8+ T cell count, and CD4+/CD8+ T cell ratio to measure systemic immune response. Our results showed that probiotics can decrease the blood LPS level in HIV-infected children undergoing ARV therapy, but they do not appear to influence the humoral mucosal immune response and systemic immune response.

Lipopolysaccharide is the main component of the Gram-negative bacteria cell wall and a potent inflammatory stimulant, which is present in measurable quantities in blood plasma. The lipopolysaccharide level can be observed as a consequence of gastrointestinal tract damage in patients with chronic infection, including those with HIV infection (4). Administration of ARV in patients with HIV infection has been known to suppress virus replication. However, evidence has shown that ARV alone does not help repair structural damage of the gastrointestinal tract, which is the main cause of bacterial translocation (14). In this study, supplementation with the probiotic *L. plantarum* IS-10506 led to a significantly lower blood LPS level in HIV-infected children who received ARV therapy.

Gori (2012) revealed that probiotic supplementation reduces microbial translocation. In this study FOS + *Lactobacillus rhamnosus* HN001 and *Bifidobacterium lactis* Bi-07 were administered to 20 adults for 16 weeks and showed decreased microbial translocation as measured by bacterial 16S rRNA,

and decreased pathogenic bacterial count in HIV-infected adults who had not received ARV therapy (1). This study is similar to work by Hunt (2010) that used prebiotics as interventional treatment that led to a decrease in both LPS and the pathogenic bacterial count after 12 weeks of intervention in 20 adults who had not received ARV therapy (16). Furthermore, another study observing synbiotic administration for 4 weeks in 28 HIV-infected women who had received ARV therapy and a study which observed probiotic and prebiotic administration in SIV-infected Asian macaques given ARV therapy did not show a change in microbial translocation nor pathogenic bacterial count (8, 18).

Various studies have shown that probiotics play a role in reducing epithelial permeability and down-regulating systemic and mucosal inflammation (19). The epithelial brush border tight junction is damaged during infection. *L. plantarum* IS-10506 and IS-20506 helped repair intestinal epithelial brush border damage due to *E. coli* lipopolysaccharide. Probiotic administration has been shown to repair such damage, marked by a simultaneous increase in *Galectin-4*, *Myosin-1a*, *Occludin* and *ZO-1* through the ERIK/MAP (extracellular regulated kinase/mitogen activated protein) and JNK/MAP kinase (c-Jun NH2 terminal kinase/mitogen activated protein) pathways (12, 18, 20). Thus, the observed decrease in microbial translocation in our study could be caused by a direct repair mechanism affecting the mucosal barrier tight junction and a decrease in gastrointestinal epithelial permeability (20).

On the contrary, previous research suggests that intestinal barrier dysfunction may be related to the sIgA level (21). However, in our study, sIgA did not show a significant increase that correlated with the significant decrease in LPS level. Thus, we concluded that the probiotic reduces the LPS level through a pathway not involving sIgA.

Furthermore, this study also showed that the probiotic did not affect either the humoral mucosal immune response or systemic immune response in HIV infected patients. Hummelen (2010) studied the effect of probiotic supplementation containing *L. rhamnosus* GR-1 and *L. reuteri* RC-14 ( $2 \times 10^9$  cfu) for 25 weeks on adult women with HIV infection. The probiotics did not affect immune system function (15). Experimental research on pigtail macaques given VSL#3 probiotic supplementation and ARV therapy showed that there was no difference in the

CD4+ T cell content of blood, although there was an increase in the CD4+ T cell counts in the digestive system (jejunum and colon) (8). Probiotic supplementation with ARV therapy was found to increase the CD4+ lymphocyte count significantly in the propria lamina cells in the small intestine of mice (8). Unfortunately, we did not measure the intestinal CD4 level.

There was no report of adverse effects or severe clinical changes during our study. Evidence showed that administration of prebiotics, probiotics, and synbiotics to immunocompromised patients due to HIV-infection did not produce significant adverse effects (20, 22). A previous study by Cunningham et al. showed that one-month administration of high dose *L. plantarum* 299v to HIV-infected children did not yield adverse effects (23). It was reported that prebiotics given to HIV-infected adults for 12 weeks cause only minor stomach discomfort and flatulence in a minority of subjects (1). A similar result was also reported in a study by Hernandez et al. using a synbiotic for 16 weeks in HIV-infected adult patients (20). The study showed no observable serious adverse effects, significant clinical changes, or occurrence of sepsis, bacteraemia, or an acute inflammatory response (20).

## CONCLUSION

From this study, we conclude that the probiotic *L. plantarum* IS-10506 can decrease the blood LPS level in HIV-infected children undergoing ARV therapy after 6 weeks of supplementation and has potential for use as a supplement for HIV-infected children who received ARV therapy. Further study is needed to specifically prove the role of probiotics in controlling microbial translocation, repairing the gastrointestinal mucosal barrier, and reducing gastrointestinal permeability, as well as to investigate the relationships among these factors.

## ACKNOWLEDGEMENTS

This research was supported by a 2009 Grant from the General Director of Higher Education, Ministry of National Education and Culture, Republic of Indonesia.

## REFERENCES

- Gori A, Rizzardini G, van't Land B, Amor KB, van Schaik J, Torti C, et al. Specific prebiotics modulate gut microbiota and immune activation in HAART-naive HIV-infected adults: results of the "COPA" pilot randomized trial. *Mucosal Immunol* 2011;4:554-563.
- UNAIDS. Fact sheet - Latest statistics on the status of the AIDS epidemic [Internet]. 2017. Available from: [http://www.unaids.org/sites/default/files/media\\_asset/20170720\\_Data\\_book\\_2017\\_en.pdf](http://www.unaids.org/sites/default/files/media_asset/20170720_Data_book_2017_en.pdf)
- Brenchley JM, Douek DC. HIV infection and the gastrointestinal immune system. *Mucosal Immunol* 2008;1:23-30.
- Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. *Nat Med* 2006;12:1365-1371.
- Vassallo M, Mercié P, Cottalorda J, Ticchioni M, Delamónica P. The role of lipopolysaccharide as a marker of immune activation in HIV-1 infected patients: a systematic literature review. *Virology* 2012;9:174.
- Marchetti G, Tincati C, Silvestri G. Microbial translocation in the pathogenesis of HIV infection and AIDS. *Clin Microbiol Rev* 2013;26:2-18.
- Shacklett BL, Anton PA. HIV infection and gut mucosal immune function: updates on pathogenesis with implications for management and intervention. *Curr Infect Dis Rep* 2010;12:19-27.
- Klatt NR, Canary LA, Sun X, Vinton CL, Funderburg NT, Morcock DR, et al. Probiotic/prebiotic supplementation of antiretrovirals improves gastrointestinal immunity in SIV-infected macaques. *J Clin Invest* 2013; 123: 903-907.
- Sandler NG, Wand H, Roque A, Law M, Nason MC, Nixon DE, et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. *J Infect Dis* 2011;203:780-790.
- Enos MK, Burton JP, Dols J, Buhulata S, Chandalu J, Reid G. Probiotics and nutrients for the first 1000 days of life in the developing world. *Benef Microbes* 2013;4:3-16.
- Reid G. The potential role for probiotic yogurt for people living with HIV/AIDS. *Gut Microbes* 2010;1:411-414.
- Collado MC, Surono IS, Meriluoto J, Salminen S. Potential probiotic characteristics of *Lactobacillus* and *Enterococcus* strains isolated from traditional dadih fermented milk against pathogen intestinal colonization. *J Food Prot* 2007;70:700-705.
- Kusuma TS, Riawan W, Made G, Ranuh RG, Surono IS. Abilities of *Lactobacillus plantarum* Strain IS-10506 and IS-20506 in inhibiting Nfkb activation, downregulating TNF Receptor-1 (tnfr1) and apopto-

- sis in epithelial brush border of *Rattus Novergicus* induced LPS. *J Kedokt Brawijaya* 2008;24:22-29.
14. Brechley J, Douek D. The mucosal barrier and immune activation in HIV pathogenesis. *Curr Opin HIV AIDS* 2008;3:356-361.
  15. Hummelen R, Vos AP, van't Land B, van Norren K, Reid G. Altered host-microbe interaction in HIV: a target for intervention with pro- and prebiotics. *Int Rev Immunol* 2010;29:485-513.
  16. Hunt PW. Th17, gut, and HIV: therapeutic implications. *Curr Opin HIV AIDS* 2010;5:189-193.
  17. Sandler NG, Douek DC. Microbial translocation in HIV infection: causes, consequences and treatment opportunities. *Nat Rev Microbiol* 2012;10:655-666.
  18. Schunter M, Chu H, Hayes TL, McConnell D, Crawford SS, Luciw PA, et al. Randomized pilot trial of a synbiotic dietary supplement in chronic HIV-1 infection. *BMC Complement Altern Med* 2012;12:84.
  19. Trois L, Cardoso EM, Miura E. Use of probiotics in HIV-infected children: a randomized double-blind controlled study. *J Trop Pediatr* 2008;54:19-24.
  20. González-Hernández LA, Jave-Suarez LF, Fafutis-Morris M, Montes-Salcedo KE, Valle-Gutierrez LG, Campos-Loza AE, et al. Synbiotic therapy decreases microbial translocation and inflammation and improves immunological status in HIV-infected patients: a double-blind randomized controlled pilot trial. *Nutr J* 2012;11:90.
  21. Devito C, Broliden K, Kaul R, Svensson L, Johansen K, Kiama P, et al. Mucosal and plasma IgA from HIV-1-exposed uninfected individuals inhibit HIV-1 transcytosis across human epithelial cells. *J Immunol* 2000;165:5170-5176.
  22. Guinane S. The effectiveness of probiotics for managing diarrhoea in people with HIV infection: a critically appraised topic. *HIV Med* 2013;14:187-190.
  23. Cunningham-Rundles S, Ahrn S, Bengmark S, Johann-Liang R, Marshall F, Metakis L, et al. Probiotics and immune response. *Am J Gastroenterol* 2000;95:S22-25.

# Source details

## Iranian Journal of Microbiology

Open Access ⓘ

Scopus coverage years: from 2010 to Present

Publisher: Tehran University of Medical Sciences

ISSN: 2008-3289 E-ISSN: 2008-4447

Subject area: Medicine: Microbiology (medical) Immunology and Microbiology: Microbiology

[View all documents >](#) [Set document alert](#) [Save to source list](#)

CiteScore 2019 **1.6** ⓘ

[Add CiteScore to your site](#)

SJR 2019 **0.329** ⓘ

SNIP 2019 **0.655** ⓘ

[CiteScore](#) [CiteScore rank & trend](#) [Scopus content coverage](#)

**i Improved CiteScore methodology** ⓘ

CiteScore 2019 counts the citations received in 2016-2019 to articles, reviews, conference papers, book chapters and data papers published in 2016-2019, and divides this by the number of publications published in 2016-2019. [Learn more >](#)

**CiteScore 2019** ▾

**1.6** =  $\frac{387 \text{ Citations 2016 - 2019}}{247 \text{ Documents 2016 - 2019}}$

Calculated on 06 May, 2020

**CiteScoreTracker 2020** ⓘ

**1.1** =  $\frac{252 \text{ Citations to date}}{221 \text{ Documents to date}}$

Last updated on 10 June, 2020 • Updated monthly

### CiteScore rank 2019 ⓘ

Category	Rank	Percentile
Medicine		
└ Microbiology (medical)	#81/115	30th
Immunology and Microbiology		
└ Microbiology	#119/147	19th

[View CiteScore methodology >](#) [CiteScore FAQ >](#) [🔗](#)

#### About Scopus

- What is Scopus
- Content coverage
- Scopus blog
- Scopus API
- Privacy matters

#### Language

- 日本語に切り替える
- 切换到简体中文
- 切换到繁體中文
- Русский язык

#### Customer Service

- Help
- Contact us

We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.





SJR

Scimago Journal &amp; Country Rank

Enter Journal Title, ISSN or Publisher Name

[Home](#) [Journal Rankings](#) [Country Rankings](#) [Viz Tools](#) [Help](#) [About Us](#)

Ads by Google

[Stop seeing this ad](#) [Why this ad?](#)

# Iranian Journal of Microbiology

**Country** [Iran](#) - SJR Ranking of Iran

**Subject Area and Category** [Immunology and Microbiology](#)  
[Microbiology](#)  
[Medicine](#)  
[Microbiology \(medical\)](#)

**Publisher** [Teheran University of Medical Sciences](#)

**Publication type** Journals

**ISSN** 20083289, 20084447

**Coverage** 2010-2020

23

H Index


**Scope** The Iranian Journal of Microbiology (IJM) is an international, multi-disciplinary, peer-reviewed journal that provides rapid publication of the most advanced scientific research in the areas of basic and applied research on bacteria and other micro-organisms, including bacteria, viruses, yeasts, fungi, microalgae, and protozoa concerning the development of tools for diagnosis and disease control, epidemiology, antimicrobial agents, clinical microbiology, immunology, Genetics, Genomics and Molecular Biology. Contributions may be in the form of original research papers, review articles, short communications, case reports, technical reports, and letters to the Editor. Research findings must be novel and the original data must be available for review by the Editors, if necessary. Studies that are preliminary, of weak originality or merely descriptive as well as negative results are not appropriate for the journal. Papers considered for publication must be unpublished work (except in an abstract form) that is not under consideration for publication anywhere else, and all co-authors should have agreed to the submission. Manuscripts should be written in English.

[Homepage](#)[How to publish in this journal](#)[Contact](#)[Join the conversation about this journal](#)


Ads by Google

[Stop seeing this ad](#) [Why this ad?](#)


Quartiles




SJR



Citations per document




Total Cites Self-Cites




● Cites / Doc. (4 years)  
● Cites / Doc. (3 years)  
● Cites / Doc. (2 years)


External Cites per Doc Cites per Doc




% International Collaboration




Citable documents Non-citable documents



Cited documents Uncited documents



Iranian Journal of Microbiology



← Show this widget in your own website

Just copy the code below and paste within your html code:

```
<a href="https://www.scima
```

 **Muhammad Ibrahim** 7 months ago

Dear Sir,

I hope you will be fine. I want to publish a paper in your Journal. What are APC and how much time will be taken in publishing?

[reply](#)



**Melanie Ortiz** 7 months ago

[Reply to this](#)

Dear Muhammad,

thank you for contacting us.

Sorry to tell you that SCImago Journal & Country Rank is not a journal. SJR is a portal with scientometric indicators of journals indexed in Elsevier/Scopus.

Unfortunately, we cannot help you with your request, we suggest you to visit the journal's homepage or contact the journal's editorial staff, so they could inform you more deeply.

Best Regards, SCImago Team

 **Reham** 2 years ago

I have Original article and I want to publishing in your Journal ( Iranian Journal of Microbiology) please help me I ready to pay the cost . thanks so much

[reply](#)

#### Leave a comment

Name

Email

(will not be published)



I'm not a robot

reCAPTCHA  
[Privacy](#) [Terms](#)

Copyright

The users of Scimago Journal & Country Rank have the possibility to dialogue through comments linked to a specific journal. The purpose is to have a forum in which general doubts about the processes of publication in the journal, experiences and other issues derived from the publication of papers are resolved. For topics on particular articles, maintain the dialogue through the usual channels with your editor.

Developed by:



Powered by:



Follow us on @ScimagoJR

Scimago Lab, Copyright 2007-2020. Data Source: Scopus®

